Organisation paid for research Program year 2025 Source: CMS Open Payments

Piedmont Eye Center

Neither a doctor nor a teaching hospital

Research payments

$3,628,358

240 payments

Through program year 2025, Piedmont Eye Center is reported as receiving $3,628,358 in research payments, across 240 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,307,850 38
2024 Research $347,468 10
2023 Research $968,026 33
2022 Research $497,668 30
2021 Research $267,193 24
2020 Research $68,420 43
2019 Research $171,732 62

Breakdown

Who paid Research payments · program years 2019–2025
  1. Roche TCRC, Inc. $1,552,625 36 payments
  2. Bausch & Lomb Americas Inc. $506,768 11 payments
  3. Novartis Pharmaceuticals Corporation $447,566 10 payments
  4. Oyster Point Pharma, Inc. $346,131 16 payments
  5. AbbVie, Inc. $235,177 34 payments
  6. Glaukos Corporation $138,642 34 payments
  7. Allergan Inc. $136,413 84 payments
  8. Padagis US LLC $123,604 5 payments
  9. Alexion Pharmaceuticals, Inc. $121,689 3 payments
  10. Perrigo Company plc $14,742 6 payments
Studies the money was for Research payments · program years 2019–2025
  1. A biomarker study to characterize response to anti-inflammatory treatment for dry eye disease $835,728 7 payments
  2. Phase 2 Study to Investigate Ro7200220 in Diabetic MacUlar Edema $599,515 16 payments
  3. A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution, Used Two Times Daily in Healthy $343,193 7 payments
  4. OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity (LYNX-3) $218,368 10 payments
  5. A Randomized, Double-Masked, Multicenter Study to Evaluate the Safety and Efficacy of Ecf843 VS Vehicle in Subjects With Dry Eye Disease $187,951 3 payments
  6. A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled Evaluation of the Onset and Duration of Action of the Combination Drug Product Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution Compared to its Components and Vehicle for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge Model $163,575 4 payments
  7. A 12-Week Parallel Group, Randomized, Placebo-Controlled, Double-Blinded, Multi-Center Study to Evaluate Efficacy and Safety of 2 Concentrations of Saf312 Eye Drops (5 MG/ML and 15 MG/ML) Used Twice-Daily in the Treatment of Post-Operative Corneal Induced $152,878 1 payment
  8. Long-term Safety and Efficacy Extension Trial of Bimatoprost SR $144,889 22 payments
  9. Multi-Center, Randomized, Double-Masked, Active Controlled, Parallel Group Study to Compare Perrigo's Brinzolamide Brimonidine Ophthalmic Suspension 1 percent to Simbrinza in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes $123,604 5 payments
  10. A Phase 2, Double Masked, Placebo Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD) $121,689 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record